Compound Details
Buy Enclomiphene Citrate (CAS 7599-79-3) by NovaTech Sciences. Pharmaceutical-grade tablets for hormone support, fertility management, and testosterone balance.
Form
Oral tablets
Strength
25 mg Enclomiphene Citrate per tablet
Packaging
Box of 10 tablets
Tablet Type
Pharmaceutical-grade, testosterone support formulation
Usage Category
Post Cycle Therapy (PCT), testosterone boosting, endocrine support
Suitable For
Athletes, bodybuilders, men recovering from steroid cycles, and users requiring hormone support
Enclominova Tablets are formulated with high-purity Enclomiphene Citrate (CAS 7599-79-3), a selective estrogen receptor modulator (SERM) recognized for its role in supporting endogenous testosterone production and hormonal balance. Identified globally by CAS 7599-79-3, Enclomiphene Citrate is widely studied for its ability to stimulate natural gonadotropin release without directly supplying external hormones.
NovaTech Sciences manufactures Enclomiphene Citrate CAS 7599-79-3 under strict pharmaceutical standards, ensuring verified chemical identity, formulation stability, and global supply reliability.
Enclomiphene Citrate, registered under CAS 7599-79-3, is the trans-isomer of clomiphene and functions as a selective estrogen receptor modulator. By interacting with estrogen receptors in the hypothalamus, Enclomiphene Citrate CAS 7599-79-3 promotes increased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
This mechanism supports natural testosterone synthesis and fertility-related hormone balance, making CAS 7599-79-3 a compound of significant pharmaceutical interest.
The primary function of Enclomiphene Citrate (CAS 7599-79-3) is to block estrogen feedback at the hypothalamic level. This action stimulates the pituitary gland to release LH and FSH, which in turn signal the testes to produce testosterone naturally.
Unlike direct testosterone therapy, Enclomiphene Citrate CAS 7599-79-3 works by enhancing the body's own endocrine signaling pathways, supporting endogenous hormone production.
Each batch of Enclomiphene Citrate CAS 7599-79-3 undergoes strict quality validation to ensure purity, stability, and dosage accuracy.
NovaTech Sciences operates as a trusted manufacturer, supplier, and exporter of Enclomiphene Citrate (CAS 7599-79-3) for international pharmaceutical markets. By clearly specifying CAS 7599-79-3, Enclominova ensures regulatory transparency and chemical authenticity.
Selecting Enclomiphene Citrate CAS 7599-79-3 from NovaTech Sciences means choosing pharmaceutical-grade quality and reliable hormone support formulation. Enclominova Tablets are developed to meet regulated market standards requiring chemical verification and consistent performance.
With emphasis on quality assurance and global compliance, NovaTech Sciences ensures dependable supply of Enclomiphene Citrate (CAS 7599-79-3) for hormone support and fertility management applications.
For those seeking a reliable source of Enclomiphene Citrate (CAS 7599-79-3), Enclominova Tablets by NovaTech Sciences provide verified chemical identity, standardized formulation, and pharmaceutical-grade manufacturing. Backed by strict quality control systems, Enclomiphene Citrate CAS 7599-79-3 remains a trusted compound for hormone balance, fertility support, and natural testosterone stimulation strategies.
Precautions
Contraindications
Enclomiphene Citrate is a selective oestrogen receptor modulator identified by CAS Number 7599-79-3. It is the citrate salt of enclomiphene, the trans-isomer found within clomiphene. The compound has been studied for its effects on hormonal signalling, particularly the relationship between oestrogen feedback, gonadotropin release and endogenous testosterone production. Its molecular formula is C32H36ClNO8.
This Nova Techsciences compound page should present Enclomiphene Citrate through accurate chemical identification, balanced scientific information and transparent regulatory context. It should not replace approved prescribing information or professional medical advice.
Enclomiphene has been investigated for secondary hypogonadism in adult men. However, the European Medicines Agency refused marketing authorisation for the enclomiphene medicine EnCyzix in 2018 because the submitted evidence did not sufficiently demonstrate a favourable balance of efficacy and safety. The page should therefore avoid presenting Enclomiphene Citrate as an authorised treatment across Europe unless a valid country-specific authorisation can be demonstrated.
A dependable Enclomiphene Citrate compound profile should be supported by appropriate documentation. Relevant controls may include raw-material identity testing, active-compound assay, impurity analysis, tablet content uniformity, dissolution assessment, stability studies and packaging-integrity checks.
Every batch should carry a unique identification number connected to its manufacturing history and laboratory-release records. Claims involving purity, pharmaceutical grade, manufacturing standards or clinical performance should only be published when supported by current and verifiable evidence.
For audiences in the Netherlands and United Kingdom, Nova Techsciences should clearly state the compound’s marketing-authorisation status, responsible manufacturer, legal supply category and adverse-event reporting procedure.
The EMA assessment identified uncertainties concerning long-term exposure and discussed possible cardiovascular, thromboembolic, visual and laboratory-related safety concerns. Enclomiphene Citrate should not be promoted for unsupervised hormone management, post-cycle therapy, bodybuilding or use by minors. Any clinical consideration requires qualified professional assessment and country-specific regulatory approval.
Metenolone Acetate is a steroid ester identified by CAS Number 434-05-9. It is chemically unrelated to Enclomiphene Citrate and belongs to the anabolic-androgenic category. Its compound page should independently address legal status, liver and cardiovascular considerations, contraindications and batch traceability.
Methyldrostanolone, also called Methasterone, is identified by CAS Number 3381-88-2. It is an orally active anabolic-androgenic compound rather than a selective oestrogen receptor modulator. Its information should prioritise regulatory status, liver-related risks, quality records and warnings against non-medical use.
Cabergoline is a dopamine-receptor agonist identified by CAS Number 81409-90-7. It is pharmacologically different from Enclomiphene Citrate and has authorised uses involving prolactin-related conditions in certain markets. Its cardiovascular precautions, interactions and prescribing requirements should be documented separately.
Liothyronine Sodium is a synthetic thyroid hormone identified by CAS Number 55-06-1. It is used in selected thyroid-related clinical settings and requires precise strength identification and thyroid-function monitoring. It should not be presented for unsupervised metabolism or weight-management purposes.
Oxandrolone is an anabolic-androgenic steroid identified by CAS Number 53-39-4. It has a completely different mechanism and safety profile from Enclomiphene Citrate. Its page should clearly address regulatory status, liver and cardiovascular warnings, contraindications and professional medical oversight.
Enclomiphene Citrate should ultimately be presented through correct CAS identification, transparent scientific evidence, documented quality controls and clearly stated regulatory limitations.
Premium aromatase inhibitor tablets for estrogen suppression and effective hormone balance support.
Buy Tamoxifen Citrate (CAS 54965-24-1) by NovaTech Sciences. Premium tablets for estrogen modulation, hormone support, and targeted receptor activity.
Buy Anastrozole (CAS 120511-73-1) by NovaTech Sciences. Pharmaceutical-grade aromatase inhibitor tablets for estrogen suppression and hormone regulation.
